Table 6 Cost, Consequences per 100 Patients, and Cost Effectiveness of Using an Initial Antirethroviral Regimen of LPV/r Followed by Efavirenz

Undiscounted QALYs

1,163

1,151

11.7

QALY months gained per person

1.41 months

QALYs discounted

944

935

9.388

Costs discounted

$32,365,777

$31,531,823

$833,953

Cost per QALY

$88,829/QALY*

5 year mean total cost/patient undiscounted

$115,219

$103,226

$11,994

10 year mean total cost/patient undiscounted

$221,428

$211,121

$10,307

Lifetime mean total cost/patient undiscounted

$413,767

$406,309

$7,458

1.8% increase for LPV/r

ANTIRETROVIRAL

BUDGET

IMPACT

LPV/r

EFV

Difference

Percent Increase

5 year cost of ARV drugs per patient (undiscounted)

$90,336

$78,536

$11,800

10 year cost of ARV drugs per patient (undiscounted)

$172,421

$162,160

$10,261

Percent Lifetime ARV budget increase estimated for using LPV/r first, per patient (undiscounted)

$279,697

$272,289

$7,408

2.7%